Interventions for Trismus in Head and Neck Cancer Patients: A Systematic Review of Randomized Controlled Trials

Shuzhen Chee, RN, MSN1*, Yasmeen M. Byrnes, BA1*, Kevin T. Chorath, MD1, Karthik Rajasekaran, MD1, and Jie Deng, PhD, RN, OCN, FAAN1†

Abstract

Background: Current treatment for head and neck cancers (HNCs) have led to an improved survival. However, the sequela of cancer treatment often result in trismus, or reduced mouth opening. The purpose of this report is to identify interventional studies for trismus management in HNC patients. Methods: A search of PubMed, Embase, Cumulated Index to Nursing and Allied Health Literature, and the Cochrane Library was conducted in March 2020 for randomized controlled trials (RCTs) involving interventions for trismus for head and neck cancer within 10 years. Intervention could involve the use of an exercise regime, jaw rehabilitation device, technological device, medication or massage therapy. The primary outcome was the measurement of mouth opening. Results: Eleven RCTs involving a total of 685 patients with HNC were included. Six RCTs evaluated the effectiveness of a jaw mobilization device with exercises; there was no significant benefit of an exercise regime with a jaw mobilization device either initiated before, during or after treatment compared to no exercise. Two RCTs compared 2 intervention groups that involved exercises only, with 1 study assessing the benefit of weekly supervised physical therapy with gum chewing and another evaluating the benefit of immediate (1-2 days) versus delayed (7-10 days) initiation of exercise post-surgery; there was no significant difference between groups in either study. One RCT that recruited only patients with trismus demonstrated that an exercise regime in combination with low-level laser therapy or low-intensity ultrasound had superior results in mouth opening measurements compared to exercise alone. Two RCTs compared intervention groups with and without follow-up reminders; both studies showed a significant improvement in mouth opening measurements in groups with follow-up reminders. Conclusion: This systematic review did not convey a clear consensus as to optimal intervention for trismus in HNC patients. A variety of exercise regimens and jaw rehabilitation devices appear to have comparable effectiveness. However, efforts focused on increasing adherence to a particular intervention protocol may positively impact mouth opening measures in head and neck cancer patients. Also, low-level laser therapy and low-intensity ultrasound coupled with exercise may be beneficial for patients with trismus.

Keywords
head and neck cancer, trismus, exercise, rehabilitation, mouth opening, systematic review, randomized controlled trial

Submitted February 19, 2021; revised February 19, 2021; accepted March 11, 2021

Introduction

Head and neck cancers (HNC) are a heterogenous group of cancers that originate from the oral cavity, oropharynx, hypopharynx, and larynx and are twice as likely to happen in men than in women. HNC is currently the eighth most common cancer in men in the United States.1 With surgery and/or radiotherapy (RT) as standard treatments in HNC coupled with chemotherapy (CT) as neoadjuvant or

1University of Pennsylvania, Philadelphia, PA, USA
*Co-first authors SC and YMB contributed equally to the manuscript.

Corresponding Author:
Jie Deng, School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA 19104-4217, USA.
Email: jiedeng@nursing.upenn.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
adjuvant therapy in advanced stage HNC, the survival of HNC has significantly improved since the late 20th century; the relative 5-year survival rate is 65% for all HNC and up to 84% for local cancers. Despite improved survival, post-surgical scarring and radiotherapy induced fibrosis in the pterygoid or masseter muscles and temporomandibular joint (TMJ) can result in adverse functional outcomes related to mouth opening, voice, speech and swallowing. These impairments may start as early as during treatment and persist for up to many years after treatment, causing acute decline in quality of life (QoL) that may not return to pre-treatment levels.

Trismus is one of the common side effects of HNC treatment, along with dysphagia, xerostomia, mucositis and radiation dermatitis. Trismus is a disorder in which patients have decreased range of motion of the muscles of mastication, resulting in inability to in opening the mouth more than 35mm. The incidence of trismus in HNC post-treatment is high and persistent; it has been found to affect up to 30.7% of HNC patients treated with chemoradiotherapy (CRT) and 39% of HNC patients treated with RT and surgery at 6 months post treatment, even with preventive exercises.

According to the existing literature, rehabilitation aimed at preventing trismus consists of either passive or active stretches to the mandible and may involve jaw mobilizing devices such as the TheraBite (Atos Medical, Horby, Sweden), Dynasplint (Dynasplint Systems, Inc., Maryland, USA) or stacked tongue depressors. Recent advances in treatment such as the use of intensity modulated radiation therapy (IMRT) have greatly decreased the prevalence of trismus and resulted in better functional outcomes. However, there remains a need to develop an evidence-based approach for trismus prevention and management given the condition’s debilitating nature. Preventative and therapeutic rehabilitation for trismus is considered the standard of care but there is currently no consensus regarding rehabilitation protocol.

The purpose of this systematic review is to (1) robustly identify interventional studies for trismus management in HNC patients, (2) assess methodological quality of the identified studies, (3) summarize results of these studies, and (4) propose future research directions in this area.

**Methods**

**Search strategy**

A comprehensive literature search was conducted between March 19, 2020 and March 26, 2020. A professional librarian experienced in health science literature search assisted with formulating, revising, and finalizing a search strategy. The search strategy included 4 major databases: PubMed, Embase, Cumulated Index to Nursing and Allied Health Literature (CINAHL), and the Cochrane library. Dated search records for all 4 databases are available in Supplemental Appendix A. All searches filtered for human studies that were written in English and published within the past 10 years were included.

A search was initially conducted in PubMed. The first set of search terms (see Supplemental Appendix A) yielded 240 articles. After reviewing the titles and abstracts of these articles in collaboration with the librarian, the search terms were broadened to include synonymous words and phrases (see Supplemental Appendix A). The expanded set of search terms yielded an additional 80 articles from PubMed.

Next, Embase and CINAHL were queried (see Supplemental Appendix A) yielding 843 and 198 articles, respectively. The Cochrane library search resulted in 10 systematic reviews and 111 clinical trials. The clinical trials were scanned for relevant articles, of which 12 out of 14 relevant studies were already identified in either PubMed, Embase or CINAHL. The full texts for the remaining 2 studies were requested and assessed.

**Screening process**

All 1482 article citations were uploaded to a citation manager (ProQuest Refworks). After removing the duplicates, articles were screened according to the evidence-based Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) system. This step-by-step process is outlined in detail in a PRISMA flow diagram (Figure 1). After a review of titles, abstracts, and full texts excluded 1275 articles (Figure 1), 52 articles remained and were considered for inclusion in the systematic review.

**Inclusion criteria**

Studies were included if they satisfied the following criteria:

- Study design: Randomized controlled trial (RCT)
- Population: Patients with HNC
- Intervention: Any management strategies for trismus or reduced mouth opening that involve the use of an exercise regimen, device, technology, medication, or massage therapy
- Outcome: Measurement of mouth opening

Two independent reviewers evaluated the 52 articles and identified a total of 11 articles that met the inclusion criteria were included in the final systematic review (Figure 1).

**Data extraction and analysis**

Data were extracted from the 11 RCTs by 2 independent reviewers using a standardized spreadsheet. Reviewers
recorded study author(s), year of publication, purpose and design, sample and setting, independent and dependent variables, intervention and control conditions, strengths and limitations, and conclusions. The senior investigator then reviewed the extracted data, and consensus was reached by discussion between the 3 parties. The 2 reviewers were also trained by a senior investigator to assess for methodological quality and risk of bias using the validated Physiotherapy Evidence Database (PEDro) scale. Both reviewers then independently assigned PEDro scores to each of the 11 RCTs using a standardized table. Subsequently, the 2 reviewers met and discussed any discrepancies; consensus was reached on but 1 item. The senior investigator reviewed this single item and made a final independent decision. This method of independent scoring by 2 reviewers with a third reviewer arbitrating a disagreement increases the accuracy of quality rating using the PEDro scale, which otherwise has an acceptable inter-rater reliability. The creators of the PEDro scale report that scores of 0 to 4 (out of 10) are considered “poor,” 4 to 5 “fair,” 6 to 8 “good,” and 9 to 10 “excellent,” and that scores of 8 or above are optimal for complex interventions such as exercise, but these classifications have not been validated.

Results

Study selection and characteristics

The combined database searches resulted in 1410 unique articles, of which 154 were assessed for full-text eligibility. In the end, 11 eligible studies were included for systematic review. Table 1 provides detailed characteristics of the
included studies. All studies were published in English, used a randomized control design, and reported the effect of interventions to improve trismus following HNC treatment. The sample sizes ranged from 27 patients to 132 patients, with a mean age ranging from 42.3 years to 67.8 years. Cancer stage varied from I to IV, and treatment modalities included radiation, surgery, chemotherapy, or combinations of the former.

**Risk of Bias in Included RCTs**

Overall, most RCTs had low risk of bias; with 10 RCTs rated at least a “fair” (≥4/10) and 6 RCTs rated “good” or higher (≥6/10); the results are presented in Table 2. Of note, no consensus cutoff PEDro scores currently exist for acceptable risk of bias. All studies described the eligibility criteria and employed a random allocation approach. However, the majority of the studies failed to blind subjects (n = 10), therapists (n = 10), and assessors (n = 7). There were also a fair number of studies who did not have adequate follow-up (n = 5); either the mouth opening was not measured in at least 85% of the allocated subjects at any time point, or information was missing. At 6 months follow-up, 2 studies reported attrition rates from 30% to 50% in either control or intervention groups and 1 study reported a 56% attrition rate that led to a premature cessation of the study.

**Data Analysis Method**

Due to the heterogeneity in specific interventions used to treat trismus in this patient population, we were unable to perform a quantitative meta-analysis. Thus, we conducted a systematic review. Table 3 highlights the interventions used by each study and a summary of results, among other variables, and can be referred to throughout the remainder of this section. Overall, there were 4 broad categories of treatment strategy employed in the 11 RCTs.

**Intervention Category 1: Exercise Regimen with Jaw Rehabilitation Device**

Six RCTs evaluated the effectiveness of a combination of jaw rehabilitation device and exercises. Intervention periods ranged from 3 to 12 months, exercise frequency ranged from 3 to 5 times per day. All but 1 RCT studied patients in the acute period (<3 months) after treatment with surgery, RT, or CCRT; the other included patients >36 months after cancer treatment. Out of the 6 RCTs in this category, one had a statistically significant difference in mouth opening between the 2 study arms. In this RCT, patients who used the TheraBite in addition to stretching exercises had higher MIO at 6 months after RT than those who did stretching exercises alone (P=.019). The remaining 5 RCTs did not have significant results. Their characteristics are described below and in greater detail in Tables 2 and 3:

- Two RCTs compared a jaw rehabilitation device (TheraBite) to a control group that did not perform any exercises at all. Neither showed a significant difference in maximal interincisor opening (MIO) 12 months after RT (P=.264 for 1 RCT and unspecified for the other).
- Three RCTs began trismus interventions prophylactically, that is, prior to cancer treatment, in all study arms. Interventions began 1 to 2 weeks before RT, 2 weeks before CCRT, or “before RT.” There were no statistical significant differences in maximal mouth opening (MMO) (P=.264) or MIO between the intervention and control groups in any of these studies.
- Two RCTs used alternatives to the conventional jaw rehabilitation devices available on the market (eg, TheraBite, Dynasplint). A “hyperboloid device” showed no benefit to mouth opening over a no-exercises control group. Wooden spatulas also did not have significantly different mouth opening outcomes when compared to TheraBite.

**Intervention Category 2: Exercise Regimen with Ultrasound or Laser Therapy**

One RCT evaluated the effectiveness of an exercise regimen with either low intensity ultrasound or low-level laser therapy, compared to a control group with exercises only. Post-intervention mouth opening measurements in both the low intensity ultrasound and the low-level laser therapy groups showed significant improvement compared to the control group (P < .05).

**Intervention Category 3: Exercise Regimen Only**

Two RCTs compared the effectiveness of various exercise regimens. Weekly supervised sessions and gum chewing exercises in addition to a standardized exercise regimen did not confer any significant benefit in MIO at 12 months’ follow-up when compared to standardized exercise alone. There was also no significant difference between MIO at 6 months post-operative follow-up in groups who received early exercise therapy (starting 1-2 days post-op) versus late exercise therapy (starting 7-10 days post-op).

**Intervention Category 4: Exercise Regimen with Increased Contact from Healthcare Provider**

Two RCTs assessed the effect of increased direct or indirect contact with providers on mouth opening outcomes. This
| Author                | No. of patients | No. dropped out | Sex (M/F) | Mean age, y (SD) [range] | Diagnosis                          | Tumor stage | Oncologic treatment | Other specific inclusion criteria                      |
|----------------------|----------------|----------------|-----------|--------------------------|-----------------------------------|-------------|---------------------|------------------------------------------------------|
| Bragante et al\textsuperscript{18} | 90             | 5              | 76/14     | 58.5 (12.5)              | Head and neck cancer              | I-IV        | RT                  | Karnofsky performance status ≥60%; MMO ≥ 10 mm        |
| Di & Li\textsuperscript{27}      | 132            | 0              | 83/49     | 44.32 (11.03)            | Nasopharyngeal carcinoma          | I-IV        | RT                  | —                                                   |
| Elgohary et al\textsuperscript{24} | 67             | 7              | 33/27     | 61.00 (6.16) 60.75 (5.09) | Head and neck cancer              | —           | —                   | —                                                   |
| Høgdal et al\textsuperscript{25} | 100            | 24             | 70/27     | 58.5 (8.6) 62.85 (5.77)  | Cancer of the oral cavity or oropharynx | I-IV        | RT                  | MIO ≤ 35 mm                                         |
| Lee et al\textsuperscript{19}    | 71             | 25             | 49/22     | —                        | Cancer of the oral cavity or oropharynx | III-IV      | RT                  | MMO ≥ 12 mm                                         |
| Loorents et al\textsuperscript{20} | 66             | 24             | 53/13     | 59.3 (10.7) [38-84] 60.2 (11.1) [19-77] | Head and neck cancer              | —           | RT                  | MIO > 35 mm                                         |
| Sandler et al\textsuperscript{26} | 30             | 15             | 14/9      | —                        | Cancer of the oral cavity or oropharynx | —           | S                   | —                                                   |
| van der Geer et al\textsuperscript{21} | 27             | 15             | 15/12     | 67.8 64.7                | Head and neck cancer              | —           | S                   | RT* MMO ≤ 35 mm                                     |
| van der Molen et al\textsuperscript{22} | 55             | 6              | 39/10     | 57 [32-75] 56 [37-78]    | Head and neck                     | III-IV      | RT                  | —                                                   |
| Wang et al\textsuperscript{28}   | 68             | 8              | 54/6      | 55.98 (11.73) [30-82]    | Oral cancer                       | I-IV        | C                   | —                                                   |
| Zatarain et al\textsuperscript{23} | 40             | 15             | 36/4      | 57.4 (11.6)              | Head and neck cancer              | II-IV       | RT                  | MIO ≥ 35 mm                                         |

Abbreviations: SCC, squamous cell carcinoma; S, surgery; C, chemotherapy; RT, radiotherapy; NPC, nasopharyngeal carcinoma; (C)RT, chemoradiotherapy; CCRT, concomitant chemoradiotherapy; B, brachytherapy; MMO, maximal mouth opening; MIO, maximal interincisal opening; DTS, dynasplint trismus system.

*Only some patients received this treatment.
Table 2. Quality Assessment of RCTs According to the PEDro Scale.

| Study            | 1. Eligibility criteria | 2. Random allocation | 3. Concealed allocation | 4. Baseline comparability | 5. Blinded subjects | 6. Blinded therapists | 7. Blinded assessors | 8. Adequate follow-up | 9. Intention-to-treat analysis | 10. Between-group comparisons | 11. Point measure and variability | Total score (out of 10) |
|------------------|------------------------|----------------------|-------------------------|---------------------------|---------------------|----------------------|---------------------|------------------------|-------------------------------|-------------------------------|-------------------------------|------------------|
| Bragante et al18 | 1                      | 1                    | 1                       | 1                         | 0                   | 0                    | 1                   | 1                      | 1                             | 1                             | 1                             | 8                |
| Di & Li27        | 1                      | 1                    | 0                       | 1                         | 0                   | 0                    | 1                   | 1                      | 0                             | 1                             | 1                             | 6                |
| Elgohary et al14 | 1                      | 1                    | 1                       | 1                         | 0                   | 0                    | 1                   | 1                      | 0                             | 1                             | 1                             | 7                |
| Høgdal et al25   | 1                      | 1                    | 1                       | 1                         | 0                   | 0                    | 1                   | 0                      | 1                             | 1                             | 1                             | 7                |
| Lee et al19      | 1                      | 1                    | 0                       | 0                         | 0                   | 0                    | 0                   | 0                      | 0                             | 0                             | 1                             | 4                |
| Loorents et al20 | 1                      | 1                    | 1                       | 1                         | 0                   | 0                    | 0                   | 0                      | 0                             | 0                             | 1                             | 4                |
| Sandler et al24  | 1                      | 1                    | 0                       | 1                         | 0                   | 0                    | 1                   | 1                      | 1                             | 1                             | 1                             | 6                |
| van der Geer et al21 | 1                  | 1                    | 1                       | 1                         | 0                   | 0                    | 0                   | 0                      | 0                             | 0                             | 1                             | 5                |
| van der Molen et al22 | 1                | 1                    | 0                       | 0                         | 0                   | 0                    | 0                   | 0                      | 1                             | 1                             | 0                             | 4                |
| Wang et al28     | 1                      | 1                    | 1                       | 1                         | 1                   | 1                    | 1                   | 1                      | 0                             | 1                             | 1                             | 9                |
| Zatarain et al23  | 1                     | 1                    | 0                       | 1                         | 0                   | 0                    | 0                   | 0                      | 0                             | 0                             | 1                             | 3                |

1 = Yes; 0 = No.

Abbreviations: RCT, randomized controlled trial; PEDro, physiotherapy evidence database.
Table 3. Interventions.

| Author | Control | Intervention 1 | Intervention 2 | Time point of intervention | Regimen of intervention | Outcome measure | Measured time points | Summary of results |
|--------|---------|----------------|----------------|---------------------------|------------------------|----------------|---------------------|------------------|
| **Intervention Category 1: Exercise regimen with jaw rehabilitation device**
| Bragante et al.¹⁸ | No exercises N = 30 | Warm up + stretching with jaw rehab device* + masticatory training with hyperboloid device N = 30 | Warm up + masticatory training with hyperboloid device N = 30 | 1-2 wk before RT until 12 mo after RT | 4× daily for 12 mo | MMO | Before start of RT Immediately after last RT session 12 mo after RT | No significant difference in MMO between the groups at the 3 assessment time points (P=.264). |
| Lee et al.¹⁹ | Mouth opening exercises with wooden spatula N = 34 | Mouth opening exercises with jaw rehab device* N = 37 | | — | Post-operative but did not specify | 5×/d for 6 mo | MMO | Baseline 3 mo after RT 6 mo after RT | No significant difference in MMO between groups, even after adjusting for several factors. |
| Loorents et al.²⁰ | No exercises N = 33 | Exercises with jaw rehab device* N = 33 | | — | Before RT and during RT until 12 mo completion | 5×/daily for 12 mo | MIO | Baseline 3 mo post RT 6 mo post RT 12 mo post RT | No significant differences in MIO between the intervention and control groups at any of the measurement points. |
| van der Geer et al.²¹ | — | Exercises with jaw rehab device*, either 4× or 6×/d N = 14 | Exercises with jaw rehab device*, 3×/d N = 13 | Multiple months after cancer treatment (divided into either ≤36 mo or >36 mo after) | 3-6×/d for 3 mo | MMO | Pre-intervention Immediately post-intervention | No significant differences in MMO between the 2 groups. |
| van der Molen et al.²² | Stretch exercises N = 25 | Stretch exercises with jaw rehab device* N = 24 | | — | Instructions given 2 wk before CCRT, over course of RT and in post treatment period | 3×/daily | MIO | Before start of RT 10 wk after completing RT | A significant decrease (ie worsening) in pre- and post-treatment maximum mouth opening (MIO), (from 50 to 47 mm, respectively; P < .01). |
| Zatarain et al.²³ | Stretching exercises N = 20 | Stretching exercises + wearing of jaw rehab device* for 30 min at a time N = 20 | | — | During RT | 3×/d during RT and until 6 mo post RT | MIO | Prior to RT Weekly during RT 1-mo post RT 3-mo post RT 6-mo post RT | A statistically significant difference between groups at 6 mo post RT, with P=.019. |

*(continued)*
| Author                   | Control                          | Intervention 1                                      | Intervention 2                                      | Time point of intervention | Regimen of intervention | Outcome measure | Measured time points | Summary of results                                                                                     |
|-------------------------|---------------------------------|-----------------------------------------------------|-----------------------------------------------------|----------------------------|-------------------------|------------------|----------------------|---------------------------------------------------------------------------------|
| Elgohary et al<sup>24</sup> | Traditional exercise therapy N=20 | Traditional exercise therapy + low intensity ultrasound N=20 | Traditional exercise therapy, + low level laser therapy N=20 | Did not specify           | 5×/wk for 4wk           | MMO              | Pre-intervention       | Post-intervention Significant improvement in post-treatment MMO in each intervention group compared to control (P<.05), and in Intervention 1 compared to Intervention 2 (P<.001). |
| Høgdal et al<sup>25</sup> | Daily exercises N=47            | Daily exercises                                     |                                                     | 1-2d after RT up to 12 mo follow up | Exercises (both groups) 5× daily for 5-6wk | MIO              | Baseline              | No significant difference in MIO between intervention and control groups at final time point. |
| Sandler et al<sup>26</sup> | —                               | Early exercise therapy beginning 1-2 d post-op N=14 | Late exercise therapy beginning 7-10 d post op N=9 | 1-2d postoperatively or 7-10d postoperatively | 3×/daily for 8wk         | MIO              | Preoperative          | No significant difference in the jaw MIO measures between the 2 treatment arms at any time point. |
| Di & Li<sup>27</sup>     | Education and follow up instructions provided at discharge N=67 | Rehab smartphone app with follow-up reminders, education materials, and twice weekly online Q&A sessions with a physician N=65 | — | 3-6mo after treatment | For 6mo | MOD              | Immediately after discharge 3mo after discharge 6mo after discharge | At 6mo after discharge, MOD incidence was significantly lower in the intervention group (P=.017). |
| Wang et al<sup>28</sup>  | Exercise program with instruction sessions N=30 | Exercise program with instruction sessions + provider phone calls to monitor progress N=30 | — | Began on discharge day and continued for 3mo after discharge | 3×/d for 3mo | MIO              | Preoperatively 1 mo postop 3mo postop | A significantly greater increase in MIO (by 10.30mm) in the intervention group than control group at 3mo follow up (P<.001). |

Abbreviations: Jaw rehab device*, TheraBite jaw motion rehabilitation system; Jaw rehab device^, jaw dynasplint system; MMO, maximal mouth opening; RT, radiation therapy; PT, physical therapy; MOD, mouth opening difficulties; MIO, maximal interincisor opening.
entailed either use of a smart-phone app\textsuperscript{27} or provider phone call\textsuperscript{28} to monitor patients’ progress and answer questions. Control groups received standard instructions about postoperative exercise regimen and follow-up appointments, but had less frequent check-ins with providers. Follow-up period ranged from 3 to 6 months. Both of these RCTs demonstrated a statistically significant increase in mouth opening in the intervention group compared to the control group.

**Discussion**

This systematic review analyzed RCTs examining nonoperative interventions for trismus in HNC patients, with interventions ranging from use of different rehab devices to specialized exercise protocols. The majority of RCTs did not show a significant difference between the intervention arm and the control arm. The authors therefore conclude that the existing RCTs on intervention for trismus do not provide a strong consensus as to the most effective intervention for trismus in HNC patients. However, our review produced an interesting and unexpected observation: that interventions focused on increasing adherence to a given treatment regimen (as shown in Di & Lee\textsuperscript{27} and Wang et al\textsuperscript{28}) may provide a significant benefit even though interventions that change the prescribed treatment regimen itself largely do not.

From the studies that pertained to rehabilitation devices, data were mixed, and there was insufficient evidence to support a superior treatment method. Only one study, which examined the Dynasplint, reported a significant difference in mouth opening between the 2 trial arms at 6 months follow up, with $P = .019$.\textsuperscript{23} However, the effect size was very small (0.5 cm), and the PEDro score for this study was the lowest out of the 11 RCTs reviewed, indicating a potentially high risk of bias. In another study, though the authors randomized patients to 2 arms, they failed to compare mouth opening data between the 2 groups.\textsuperscript{30} They did, however, demonstrate a significant improvement in mouth opening within the entire cohort over the length of the study period, suggesting that more than 1 treatment strategy can be effective. The 4 remaining studies\textsuperscript{18-21} compared rehab devices (eg, TheraBite) to control groups and did not find a significant difference.

Two additional studies examined the effect of either the content or timing, respectively, of exercise-based therapy alone.\textsuperscript{25,26} Neither found a significant difference between study arms. These results, along with the rehab device results discussed in the previous paragraph, are concordant with the broader literature, including non-RCTs. Case series examining interventions such as devices, exercises, and even medications have shown improvement in mouth opening measurements over the study period, further supporting the claim that multiple methods can be effective.\textsuperscript{31-34} Case-control studies have shown mixed results, with some showing a significant difference between intervention and control groups, and others not.\textsuperscript{35-40} The existing body of literature further supports our review’s conclusion that there is still no clear consensus for optimal trismus management.

In some ways a subcategory of its own, Elgohary et al\textsuperscript{24} compared exercise therapy plus either low intensity ultrasound (LIUS) or low-level laser therapy (LLLT) with exercise therapy alone. Unlike most other RCTs, results showed a significant benefit in mouth opening in both treatment groups compared to exercise therapy alone. Of note, the study population also included patients who developed trismus and pain, unlike other RCTs in this review, which recruited patients after cancer treatment whether or not they already had restrictions in mouth opening. This result is interesting and deserving of further study, although it could have been confounded by adherence. After receiving LIUS and LLLT, patients in the intervention groups underwent exercise therapy in the office, whereas the control group patients received only home-based exercise therapy. Adherence data for the home-based exercise therapy was not reported. The importance of this possible confounder is supported by results from the last 2 RCTs, which looked at methods to increase treatment adherence.

Di & Li developed a smartphone app with (1) reminders for follow-up appointments, (2) educational resources, (3) biweekly opportunities for virtual consultation with physicians. They found that patients who used the app had a significantly lower incidence of mouth opening difficulties at 6 months’ follow-up than a control group with the same prescribed exercise regimen but no app ($P = .017$).\textsuperscript{27} In the other RCT,\textsuperscript{28} both intervention and control groups received instructions to complete a particular exercise programs, but the intervention group also received regular phone calls from a provider to monitor progress. There was a significantly greater increase in mouth opening in the intervention group than control, with an effect size of 10.3 mm ($P < .001$).\textsuperscript{28} These results suggest that efforts focused on increasing adherence to a particular intervention regimen may positively impact trismus-related outcome measures. Existing literature may support this concept. For example, Bragante et al\textsuperscript{18} conducted a subgroup analysis in which adherent patients had significantly higher mouth opening measurements than nonadherent patients.

Strengths of this systematic review included a broad search of 4 databases, inclusion of only RCTs, and a rigorous review of RCT quality via the validated PEDro scale. Limitations included a small final number of randomized controlled trials, heterogeneity between the studies which precluded a direct comparison of data through meta-analysis and high risk of bias in some of the RCTs due to high attrition rates. Forty-five percent of the trials (n = 5/11) had an >15% attrition rate and thus scored 0 on the PEDro scale.\textsuperscript{16} Although there is no particular level of loss to follow-up at which attrition related bias becomes an issue, it is a source of bias if the characteristics of the participants lost to follow up differ between the randomized groups and these
characteristics are correlated to the primary outcome measure. High attrition rates in trials involving supportive care for oncology population and have been reported to be 28% for primary endpoint and 44% for end-of-study endpoint; main reasons were patient withdrawal due to high symptom burden and clinical deterioration.

Some of the included RCTs also had heterogeneity with regard to primary tumor location, which could have influenced their conclusions. For certain head and neck cancers such as nasopharyngeal or malignant parapharyngeal tumors, trismus may be one of the first signs. Trismus may also be a sequela of lymphedema, an insidious and often neglected adverse effect of HNC treatment. Sandler et al found that patients with oral tumors had overall smaller jaw opening, a difference that was statistically significant at 6-month post-operative assessment. Conversely, primary tumor site had no significant impact in mouth opening at 12 months in Hogdal et al (P = .63). Other authors did not conduct a formal analysis of the impact of primary tumor site, but acknowledged the influence of this heterogeneity on mouth opening and rehabilitation outcomes, and suggested stratification based on primary tumor location and treatment in future studies.

Conclusion
This systematic review demonstrated that, thus far, no superior strategy has emerged for treatment of trismus in HNC patients; a variety of exercise regimens and rehab devices have comparable effectiveness. Interventions focusing on increasing adherence may increase mouth opening progress in HNC patients. Low-level laser therapy and low-intensity ultrasound coupled with exercise may also be beneficial for patients with trismus, but further investigation is needed. Clearly, more rigorously designed, high-quality clinical trials are needed to determine optimal interventions for treatment of trismus in HNC patients.

Acknowledgments
The authors have no other acknowledgments to declare.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Jie Deng, PhD was supported by a Research Scholars Grant, RSG-16-207-01-PCSM, from the American Cancer Society. The American Cancer Society did not have a role in study design, collection, analysis, and interpretation of data and in writing the manuscript.

ORCID iDs
Yasmeen M. Byrnes https://orcid.org/0000-0003-1392-0175
Jie Deng https://orcid.org/0000-0002-2553-8822

Supplemental Material
Supplemental material for this article is available online.

References
1. American Cancer Society. Cancer facts and figures 2020. Published 2020. Accessed October 1, 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
2. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15:994-1001. doi:10.1634/theoncologist.2009-0289
3. Wang CJ, Huang EY, Hsu HC, Chen HC, Fang FM, Hsiung CY. The degree and time-course assessment of radiation-induced trismus occurring after radiotherapy for nasopharyngeal cancer. Laryngoscope. 2005;115:1458-1460. doi:10.1097/01.mlg.0000171019.80351.46
4. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010;28:2732-2738. doi:10.1200/JCO.2009.24.6199
5. Karlsson T, Johansson M, Andrell P, Finizia C. Effects of voice rehabilitation on health-related quality of life, communication and voice in laryngeal cancer patients treated with radiotherapy: a randomised controlled trial. Acta Oncol (Madr). 2015;54:1017-1024. doi:10.3109/0284186X.2014.995773
6. Lazarus CL, Husaini H, Hu K, et al. Functional outcomes and quality of life after chemoradiotherapy: baseline and 3 and 6 months post-treatment. Dysphagia. 2014;29:365-375. doi:10.1007/s00455-014-9519-8
7. Wilson IA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer treatment: patients’ perspectives. Otolaryngol Head Neck Surg. 2011;145:767-771. doi:10.1177/0194599811414506
8. Hunter KU, Jolly S. Clinical review of physical activity and functional considerations in head and neck cancer patients. Support Care Cancer. 2013;21:1475-1479. doi:10.1007/s00520-013-1736-4
9. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. Accessed October 1, 2020. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
10. Dijkstra PU, Huisman PM, Rooben JLN. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg. 2006;35:337-342. doi:10.1016/j.ijom.2005.08.001
11. Bensadoun RJ, Rieseneck D, Lockhart PB, Elting LS, Spijkervert FKL, Brennan MT. A systematic review of trismus induced by cancer therapies in head and neck cancer patients. Support Care Cancer. 2010;18:1033-1038. doi:10.1007/s00520-010-0847-4
12. Baldoman D, Vandenbrink R. Physical therapy challenges in head and neck cancer. *Cancer Treat Res.* 2018;174:209-223. doi:10.1007/978-3-319-65421-8_12
13. Kerr P, Myers CL, Butler J, Alessa M, Lambert P, Cooke AL. Prospective functional outcomes in sequential population-based cohorts of stage III/IV oropharyngeal carcinoma patients treated with 3D conformal vs. intensity-modulated radiotherapy. *J Otolaryngol Head Neck Surg.* 2015;44:17. doi:10.1186/s40463-015-0068-4
14. Kamstra JI, van Leeuwen M, Roodegun JLN, Dijkstra PU. Exercise for trismus secondary to head and neck cancer: a systematic review. *Head Neck.* 2017;39:2352-2362. doi:10.1002/hed.24859
15. Cohen EEW, LaMonte SJ, Erb NL, et al. American cancer society head and neck cancer survivorship care guideline. *CA Cancer J Clin.* 2016;66:203-239. doi:10.3322/caac.21343
16. PEDro, the Physiotherapy Evidence Database. Updated 1999. Accessed April 15, 2020. https://pedro.org.au/wp-content/uploads/PEDro_scale.pdf
17. Moseley A, Maher C, Herbert R, Sherrington C. Reliability of a scale for measuring the methodological quality of clinical trials. In: The best evidence for health care: the role of The Cochrane Collaboration. Abstracts of the 7th Cochrane Colloquium, Rome, Italy, 5-9 October, 1999.
18. Bragante KC, Groisman S, Carboni C, et al. Efficacy of exercise therapy during radiotherapy to prevent reduction in mouth opening in patients with head and neck cancer: a randomized controlled trial. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2020;129:27-38. doi:10.1016/j.oooo.2019.09.011
19. Lee R, Yeo ST, Rogers SN, et al. Randomised feasibility study to compare the use of Therabite® with wooden spatulas to relieve and prevent trismus in patients with cancer of the head and neck. *Br J Oral Maxillofac Surg.* 2018;56:283-291. doi:10.1016/j.bjoms.2018.02.012
20. Loorens V, Rosell J, Karlsson C, Lidbäck M, Hultman K, Börjeson S. Prophylactic training for the prevention of radiotherapy-induced trismus - a randomised study. *Acta Oncol (Madr).* 2014;53:530-538. doi:10.3109/0284186X.2014.892211
21. van der Geer SJ, Reintsema H, Kamstra JI, Roodegun JLN, Dijkstra PU. The use of stretching devices for treatment of trismus in head and neck cancer patients: a randomized controlled trial. *Support Care Cancer.* 2020;28:9-11. doi:10.1007/s00520-019-05075-7
22. van der Molen L, van Rossum MA, Burkhead LM, Smeele LE, Rasch CRN, Hilgers FJM. A randomized preventive rehabilitation trial in advanced head and neck cancer patients treated with chemoradiotherapy: feasibility, compliance, and short-term effects. *Dysphagia.* 2011;26:155-170. doi:10.1007/s00545-010-9288-y
23. Zatarain LA, Smith DK, Deng J, et al. A randomized feasibility trial to evaluate use of the jaw dysnapsplint to prevent trismus in patients with head and neck cancer receiving primary or adjuvant radiation-based therapy. *Integr Cancer Ther.* 2018;17:960-967. doi:10.1177/1534735418784363
24. Elghory HM, Eladl HM, Soliman AH, Soliman ES. Effects of ultrasound, laser and exercises on temporomandibular joint pain and trismus following head and neck cancer. *Ann Rehabil Med.* 2018;42:846-853. doi:10.5535/arm.2018.42.6.846
25. Høgdal N, Juhl C, Aadahl M, Gluud C. Early preventive exercises versus usual care does not seem to reduce trismus in patients treated with radiotherapy for cancer in the oral cavity or oropharynx: a randomised clinical trial. *Acta Oncol (Mad)*. 2015;54:80-87. doi:10.3109/0284186X.2014.954677
26. Sandler ML, Lazarus CL, Ru M, et al. Effects of jaw exercise intervention timing on outcomes following oral and oropharyngeal cancer surgery: pilot study. *Head Neck.* 2019;41:3806-3817. doi:10.1002/hed.25908
27. Di R, Li G. Use of a smartphone medical app improves complications and quality of life in patients with nasopharyngeal carcinoma who underwent radiotherapy and chemotherapy. *Med Sci Monit.* 2018;24:6151-6156. doi:10.12659/MSM.908146
28. Wang TJ, Su JH, Leung KW, Liang SY, Wu SF, Wang HM. Effects of a mouth-opening intervention with remote support on adherence, the maximum interincisal opening, and mandibular function of postoperative oral cancer patients: a randomized clinical trial. *Eur J Oncol Nurs.* 2019;40:111-119. doi:10.1016/j.ejon.2019.04.001
29. Moseley AM, Rahman P, Wells GA, et al. Agreement between the Cochrane risk of bias tool and Physiotherapy Evidence Database (PEDro) scale: a meta-epidemiological study of randomized controlled trials of physical therapy interventions. *PLoS One.* 2019;14:e0222770. doi:10.1371/journal.pone.0222770
30. van der Molen L, van Rossum MA, Jacobi I, et al. Pre- and posttreatment voice and speech outcomes in patients with advanced head and neck cancer treated with chemoradiotherapy: expert listeners’ and patient’s perception. *J Voice.* 2012;26:664.e25-664.e33. doi:10.1016/j.jvoice.2011.08.016
31. Barañano CF, Rosenthal EL, Morgan BA, McCulloch NL, Magnuson JS. Dynasplint for the management of trismus after treatment of upper aerodigestive tract cancer: a retrospective study. *Ear Nose Throat J.* 2011;90:584-590. doi:10.1177/014556131109001209
32. Kamstra JI, Roodegun JLN, Beurskens CHG, Reintsema H, Dijkstra PU. Therabite exercises to treat trismus secondary to head and neck cancer. *Support Care Cancer.* 2013;21:951-957. doi:10.1007/s00520-012-1610-9
33. Kamstra JI, Reintsema H, Roodegun JLN, Dijkstra PU. Dynasplint Trismus System exercises for trismus secondary to head and neck cancer: a prospective explorative study. *Support Care Cancer.* 2016;24:3315-3323. doi:10.1007/s00520-016-3131-4
34. Stubblefield MD, Manfield L, Riedel ER. A preliminary study to compare the use of Therabite® with wooden spatulas to relieve and prevent trismus in patients with head and neck cancer. *Ann Rehabil Med.* 2018;42:846-853. doi:10.5535/arm.2018.42.6.846
35. Shulman DH, Shipman B, Willis BF. Treating trismus with dynamic splinting: a cohort, case series. *Adv Ther.* 2008;25:9-16. doi:10.1007/s12325-008-0067-0
36. González-Arriagada WA, Ramos LMA, Andrade MAC, Lopes MA. Efficacy of low-level laser therapy as an auxiliary treatment for the management of trismus in patients treated with 3D conformal vs. intensity modulated radiotherapy. *Integr Cancer Ther.* 2018;17:960-967. doi:10.1177/1534735418784363
tool for management of acute side effects of head and neck radiotherapy. *J Cosmet Laser Ther.* 2018;20:117-122. doi:10.1080/14764172.2017.1376097

37. Li H, Yao Q, Huang X, Zhuo X, Lin J, Tang Y. Therapeutic effect of pregabalin on radiotherapy-induced trismus in nasopharyngeal carcinoma patients. *Eur Ann Otorhinolaryngol Head Neck Dis.* 2019;136:251-255. doi:10.1016/j.anorl.2018.10.018

38. Pauli N, Fagerberg-Mohlin B, Andréll P, Finizia C. Exercise intervention for the treatment of trismus in head and neck cancer. *Acta Oncol (Madr).* 2014;53(4):502-509. doi:10.3109/0284186X.2013.837583

39. Rose T, Leco P, Wilson J. The development of simple daily jaw exercises for patients receiving radical head and neck radiotherapy. *J Med Imaging Radiat Sci.* 2009;40:32-37. doi:10.1016/j.jmir.2009.01.002

40. Li YH, Chang WC, Chiang TE, Lin CS, Chen YW. Mouth-opening device as a treatment modality in trismus patients with head and neck cancer and oral submucous fibrosis: a prospective study. *Clin Oral Investig.* 2019;23:469-476. doi:10.1007/s00784-018-2456-4

41. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. *Br Med J.* 2006;332:969-971. doi:10.1136/bmj.332.7547.969

42. Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. *Cancer.* 2013;119:1098-1105. doi:10.1002/cncr.27854

43. Deng J, Ridner SH, Dietrich MS, et al. Prevalence of secondary lymphedema in patients with head and neck cancer. *J Pain Symptom Manage.* 2012;43:244-252. doi:10.1016/j.jpainsymman.2011.03.019